At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 563 enrolled
Drug / intervention
ABP 654 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating ABP 654 and Ustekinumab for Plaque Psoriasis. Completed, enrolled 563 participants across 84 sites in 8 countries.
Detailed Summary
The purpose of the study is to evaluate the efficacy, safety, and immunogenicity of ABP 654 compared with ustekinumab in participants with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada, Estonia, Germany, Hungary, Latvia, Lithuania, Poland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartNov 2020
Primary CompletionJan 2022
Study CompletionJun 2022
TodayJul 2026
First PostedOct 29, 2020
Enrollment StartNov 11, 2020
Primary CompletionJan 13, 2022
Study CompletionJun 3, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.7 years ago
Interventions
ABP 654drug
Participants will receive SC injection of ABP 654.
Ustekinumabdrug
Participants will receive SC injection of ustekinumab.